Arcadia Biosciences Faces Nasdaq Delisting Over Sub-$1 Bid Price
RKDA sits 21% above its 52-week low of $0.59.
Summary
Arcadia Biosciences received a Nasdaq delisting notice on August 4, 2026, after its stock traded below $1 for 30 consecutive business days. The company has until February 1, 2027, to regain compliance, likely through a reverse stock split that shareholders will vote on soon.
Key Events · Legal and Risk Events · RKDA
-
Nasdaq Delisting Notice Received
On August 4, 2026, Nasdaq notified Arcadia Biosciences that its common stock had closed below $1.00 for 30 consecutive business days, violating the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
-
180-Day Compliance Period
The company has until February 1, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of ten consecutive business days. An additional 180-day period may be available if certain conditions are met.
-
Reverse Stock Split as Primary Cure
Management intends to evaluate options including a reverse stock split, which is already the subject of a pending shareholder vote per the July 31, 2026 preliminary proxy. Failure to regain compliance could lead to delisting.
-
Deepening Financial Distress
The delisting notice follows a going-concern warning, a $4.4 million Q1 net loss, a $4 million dilutive private placement, and a debt default, underscoring the company's precarious financial position.
Analysis · RKDA · Energy & Transportation
Nasdaq has formally notified Arcadia Biosciences that its stock no longer meets the $1 minimum bid price requirement, triggering a 180-day compliance period that runs through February 1, 2027. The notice arrives amid severe financial distress — a going-concern warning, a recent $4 million dilutive placement, and a pending shareholder vote on a reverse stock split. It crystallizes the immediate listing risk and raises the stakes for the upcoming reverse split vote. Should the reverse split fail or the stock fail to sustain a $1 bid afterward, delisting to the OTC becomes a real possibility, which would further impair liquidity and access to capital.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 46.5% of the 301 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RKDA was trading at $0.72 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.59 to $6.71. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.